 Akers Biosciences, Inc. the Company or we AKER, a developer of rapid health information technologies, today announced the closing of its previously announced public offering of 613,500 common units at a public offering price of 4.00 per unit and 1,376,500 pre-funded units at a public offering price of 3.9999 per pre-funded unit, raising gross proceeds of 7.96 million, before deducting placement agents fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised. H.C. Wainwright Co. is acted as exclusive placement agent for the offering. Each unit sold in this offering is comprised of one share of common stock and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. 